The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2006-01-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/JPET.105.093229PMID 16192315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions

  2005cited by this paper
• IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM

  2005cited by this paper
• Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.

  2005cited by this paper
• IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE

  2005cited by this paper
• Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

  2005cited by this paper
• BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4

  2005cited by this paper
• Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

  2004cited by this paper
• Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide

  2004cited by this paper
• Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol

  2004cited by this paper
• Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

  2004cited by this paper
• 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.

  2004cited by this paper
• PREDICTION OF CYTOCHROME P 450 3 A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES

  2004cited by this paper
• Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man

  2004cited by this paper
• Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration.

  2004cited by this paper
• Effect of fluconazole on theophylline disposition in humans

  2004cited by this paper
• ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION

  2004cited by this paper
• Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.

  2004cited by this paper
• Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy Volunteers

  2004cited by this paper
• Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

  2004cited by this paper
• Impact of parallel pathways of drug elimination and mutiple CYP involvement in drug-drug interactions: CYP2D6 paradigm

  2004influential reference
• Validated assays for human cytochrome P450 activities.

  2004influential reference
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

  2004cited by this paper
• Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.

  2004cited by this paper
• Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers

  2004cited by this paper
• Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects

  2004cited by this paper
• Cytochrome P450 3A expression and activity in the human small intestine

  2004influential reference
• Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

  2003cited by this paper
• Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent

  2003cited by this paper
• Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.

  2003cited by this paper
• Pharmacokinetic and Pharmacodynamic Evaluation of the Inhibition of Alprazolam by Citalopram and Fluoxetine

  2003cited by this paper
• Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.

  2003cited by this paper
• Effect of Mibefradil on CYP3A4 In Vivo

  2003cited by this paper
• Physiological approaches to the prediction of drug-drug interactions in study populations.

  2003cited by this paper
• Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.

  2003cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies

  2003influential reference
• Drug metabolism and drug interactions: application and clinical value of in vitro models.

  2003cited by this paper
• Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.

  2003cited by this paper
• Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.

  2003cited by this paper
• The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam

  2003cited by this paper
• Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.

  2003influential reference
• Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.

  2003cited by this paper
• Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide

  2003cited by this paper
• Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.

  2003cited by this paper
• Bacterial pneumonia can increase serum concentration of clozapine

  2002cited by this paper
• Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers.

  2002cited by this paper
• Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.

  2002cited by this paper
• Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

  2002cited by this paper
• Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.

  2002cited by this paper
• Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance

  2002cited by this paper
• Inhibition-based metabolic drug-drug interactions: predictions from in vitro data.

  2002cited by this paper
• Effect of Terbinafine on the Pharmacokinetics and Pharmacodynamics of Desipramine in Healthy Volunteers Identified as Cytochrome P450 2D6 (CYP2D6) Extensive Metabolizers

  2002cited by this paper
• Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin

  2001cited by this paper
• Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus

  2001cited by this paper
• Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.

  2001cited by this paper
• Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.

  2001cited by this paper
• Optimising drug development: Strategies to assess drug metabolism/transporter interaction potential - Towards a consensus

  2001cited by this paper
• Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide

  2001cited by this paper
• Pharmacokinetic Drug Interaction Potential of Risperidone With Cytochrome P450 Isozymes as Assessed by the Dextromethorphan, the Caffeine, and the Mephenytoin Test

  2001cited by this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000influential reference
• Lack of effect of sertraline on the pharmacokinetics of alprazolam.

  2000cited by this paper
• Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.

  2000cited by this paper
• Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir

  2000cited by this paper
• Plasma concentrations of active simvastatin acid are increased by gemfibrozil

  2000cited by this paper
• Effect of Clarithromycin on the Pharmacokinetics of Tolbutamide

  2000cited by this paper
• Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers

  2000cited by this paper
• Effects of metronidazole on midazolam metabolism in vitro and in vivo

  2000cited by this paper
• Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

  2000cited by this paper
• Effect of citalopram on plasma levels of oral theophylline.

  2000cited by this paper
• Quantitative Prediction of In Vivo Drug-Drug Interactions from In Vitro Data Based on Physiological Pharmacokinetics: Use of Maximum Unbound Concentration of Inhibitor at the Inlet to the Liver

  2000cited by this paper
• Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.

  2000cited by this paper
• THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*

  2000cited by this paper
• Open‐Label, Nonrandomized Study of the Effects of Gatifloxacin on the Pharmacokinetics of Midazolam in Healthy Male Volunteers

  2000cited by this paper
• Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo information.

  2000cited by this paper
• Simvastatin Does Not Affect CYP3A Activity, Quantified by the Erythromycin Breath Test and Oral Midazolam Pharmacokinetics, in Healthy Male Subjects

  2000cited by this paper
• Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam

  1999cited by this paper
• Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

  1999cited by this paper
• PHARMACOKINETIC INTERACTION BETWEEN DILTIAZEM AND TOLBUTAMIDE

  1999cited by this paper
• Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.

  1999cited by this paper
• Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

  1999cited by this paper
• Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism.

  1999cited by this paper
• Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues

  1999cited by this paper
• Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.

  1999cited by this paper
• CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

  1999influential reference
• Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.

  1999cited by this paper
• Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

  1998cited by this paper
• Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.

  1998cited by this paper
• The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

  1998cited by this paper
• Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone

  1998cited by this paper
• The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone

  1998cited by this paper
• Effect of Terbinafine on Theophylline Pharmacokinetics in Healthy Volunteers

  1998cited by this paper
• The Role of Cytochrome P450 3A4 in Alfentanil Clearance: Implications for Interindividual Variability in Disposition and Perioperative Drug Interactions

  1997cited by this paper
• Evaluation of Effects of Terbinafine on Single Oral Dose Pharmacokinetics and Anticoagulant Actions of Warfarin in Healthy Volunteers

  1997cited by this paper
• Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S‐mephenytoin

  1997cited by this paper
• A Study of the Potential Effect of Sertraline on the Pharmacokinetics and Protein Binding of Tolbutamide

  1997cited by this paper
• Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.

  1997cited by this paper
• The effect of sertraline on the pharmacokinetics of desipramine and imipramine

  1997cited by this paper
• Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.

  1997cited by this paper
• Biotransformation of clozapine in humans.

  1997influential reference
• Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.

  1997influential reference

• Advances and Challenges for Drug Interaction Evaluation - Perspectives on the ICH M12 Guideline

  2026cites this paper
• Positioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug Design.

  2025cites this paper
• Potent Antisickling Furaldehyde Analogs for Acute Sickle Cell Therapy: Enhanced Efficacy and Intravenous Formulation Potential

  2025cites this paper
• An in vitro evaluation of common botanical extracts on carboxylesterase 1 catalytic activity.

  2025cites this paper
• Role of metabolites in drug-drug interactions.

  2025cites this paper
• Computational screening identifies selective aldose reductase inhibitors with strong efficacy and limited off target interactions

  2025influential citation
• Inhibition of Cytochrome P-450 2C9 pathways attenuated flow-mediated dilation in Males but not Females.

  2025cites this paper
• The strong clinical interaction between bupropion and CYP2D6 is primarily mediated through bupropion metabolites and their stereoisomers: A paradigm for evaluating metabolites in drug-drug interaction risk.

  2025cites this paper
• Utility of PBPK Modeling in Predicting and Characterizing Clinical Drug Interactions.

  2024cites this paper
• Projections of Drug-Drug Interactions Caused by Time-Dependent Inhibitors of Cytochrome P450 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 Using In Vitro Data in Static and Dynamic Models

  2024influential citation
• Heterotropic Allosteric Modulation of CYP3A4 In Vitro by Progesterone: Evidence for Improvement in Prediction of Time Dependent Inhibition for Macrolides.

  2024cites this paper
• Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids

  2024cites this paper
• Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach

  2024cites this paper
• Model-Informed Dosing Optimization of Tacrolimus for Concomitant Administration With Itraconazole to Japanese Lung Transplant Recipients

  2024influential citation
• Clinical Trial Data-Driven Risk Assessment of Drug–Drug Interactions: A Rapid and Accurate Decision-Making Tool

  2024cites this paper
• Improvement in static and dynamic projections of drug-drug interactions caused by cytochrome P4503A time-dependent inhibitors through in vitro allosteric modulation by progesterone.

  2024cites this paper
• Inhibitory Effect of Two Carbonic Anhydrases Inhibitors on the Activity of Major Cytochrome P450 Enzymes

  2024influential citation
• Development of a Dihydroquinoline–Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N-Methyl-d-aspartate Receptor

  2023cites this paper
• Fluorescence-Based High-Throughput Assays for Investigating Cytochrome P450 Enzyme-Mediated Drug–Drug Interactions

  2023cites this paper
• Toxicological and pharmacokinetic properties of sucralose-6-acetate and its parent sucralose: in vitro screening assays

  2023cites this paper
• Special Section on New and Emerging Areas and Technologies in Drug Metabolism and Disposition, Part I — Minireview Fluorescence-Based High-Throughput Assays for Investigating Cytochrome P450 Enzyme-Mediated Drug – Drug Interactions

  2023cites this paper
• Expanding the toolbox of metabolically stable lipid prodrug strategies

  2023cites this paper
• Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates

  2023cites this paper
• Quantitative prediction of CYP3A‐mediated drug–drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

  2023cites this paper
• Inhibitory Mechanisms of Lekethromycin in Dog Liver Cytochrome P450 Enzymes Based on UPLC-MS/MS Cocktail Method

  2023cites this paper
• Pharmacokinetic interaction of voriconazole and clarithromycin in Pakistani healthy male volunteers: a single dose, randomized, crossover, open-label study

  2023cites this paper
• Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.

  2022cites this paper
• Bulleyaconitine A is a sensitive substrate and competitive inhibitor of CYP3A4: One of the possible explanations for clinical adverse reactions.

  2022cites this paper
• Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction

  2022cites this paper
• Comparative Study of Binding Pockets in Human CYP1A2, CYP3A4, CYP3A5, and CYP3A7 with Aflatoxin B1, a Hepato-Carcinogen, by Molecular Dynamics Simulation & Principal Component Analysis.

  2022cites this paper
• Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development

  2022influential citation
• Do differences in cell lines and methods used for calculation of IC50 values influence categorisation of drugs as P-glycoprotein substrates and inhibitors?

  2022cites this paper
• Cytochrome P450 isoforms contribution, plasma protein binding, toxicokinetics of enniatin A in rats and in vivo clearance prediction in humans.

  2022cites this paper
• An Automated Cocktail Method for In Vitro Assessment of Direct and Time-Dependent Inhibition of Nine Major Cytochrome P450 Enzymes - Application to Establishing CYP2C8 Inhibitor Selectivity.

  2021cites this paper
• Cytochrome P450 enzymes: a review on drug metabolizing enzyme inhibition studies in drug discovery and development.

  2021cites this paper
• In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions.

  2021cites this paper
• Application of Deep Neural Network Models in Drug Discovery Programs

  2021cites this paper
• Prediction of herb-drug interactions involving consumption of furanocoumarin-mixtures and cytochrome P450 1A2-mediated caffeine metabolism inhibition in humans.

  2021cites this paper
• Kratom Alkaloids: Interactions With Enzymes, Receptors, and Cellular Barriers

  2021cites this paper
• Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes

  2021influential citation
• Tumor reversion: a dream or a reality

  2021cites this paper
• ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.

  2021cites this paper
• Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.

  2021cites this paper
• Mechanism of dasabuvir inhibition of acetaminophen glucuronidation.

  2021cites this paper
• Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

  2021cites this paper
• The Reduction of the Combined Effects of Aflatoxin and Ochratoxin A in Piglet Livers and Kidneys by Dietary Antioxidants

  2021cites this paper
• Contribution of Extrahepatic Aldehyde Oxidase Activity to Human Clearance

  2021cites this paper
• Targeting the initiation and termination codons of SARS-CoV-2 spike protein as possible therapy against COVID-19: the role of novel harpagide 5-O-β-D-glucopyranoside from Clerodendrum volubile P Beauv. (Labiatae)

  2020cites this paper
• In vitro characterization and in vitro to in vivo predictions of drug-drug interactions

  2020cites this paper
• Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450

  2020cites this paper
• MTMA: Multi-task multi-attribute learning for the prediction of adverse drug-drug interaction

  2020cites this paper
• Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P45

  2020cites this paper
• Water-soluble copper(II) complexes with 4,5-dichloro-isothiazole-3-carboxylic acid and heterocyclic N-donor ligands: Synthesis, crystal structures, cytotoxicity, and DNA binding study

  2020cites this paper
• Using in vitro methods to determine P450s responsible for metabolism and discrimination from other oxidative pathways

  2020cites this paper
• Propranolol is a mechanism‐based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6‐transgenic mice: Effects on activity and drug responses

  2020influential citation
• Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants

  2020cites this paper
• VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions

  2020cites this paper
• O-alkyl hydroxamates display potent and selective antileishmanial activity.

  2020cites this paper
• In vitro modulation of cytochrome P450 isozymes and pharmacokinetics of caffeine by extracts of Hibiscus sabdariffa Linn calyx

  2019cites this paper
• Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters.

  2019cites this paper
• Exploration of Cytochrome P450 Inhibition Mediated Drug-Drug Interaction Potential of Kratom Alkaloids.

  2019cites this paper
• Improving natural product research translation: From source to clinical trial

  2019cites this paper
• Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

  2019cites this paper
• Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria.

  2019cites this paper
• Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure

  2019cites this paper
• Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations

  2019cites this paper
• Design, Synthesis and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).

  2019cites this paper
• Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors

  2019cites this paper
• Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes)

  2019cites this paper
• Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation

  2019cites this paper
• Design, synthesis, and antimicrobial evaluation of 1,4-dihydroindeno[1,2-c]pyrazole tethered carbohydrazide hybrids: exploring their in silico ADMET, ergosterol inhibition and ROS inducing potential.

  2019cites this paper
• Time‐dependent inhibition of carbamazepine metabolism by piperine in anti‐epileptic treatment

  2019cites this paper
• Effects and Mechanism of Nano-Copper Exposure on Hepatic Cytochrome P450 Enzymes in Rats

  2018cites this paper
• In‐vitro metabolism, CYP profiling and metabolite identification of E‐ and Z‐ guggulsterone, a potent hypolipidmic agent

  2018cites this paper
• Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation

  2018cites this paper
• New insights in the in vitro characterisation and molecular modelling of the P‐glycoprotein inhibitory promiscuity

  2018cites this paper
• Predictions of bisphenol A hepatic clearance in the isolated perfused rat liver (IPRL): impact of albumin binding and of co-administration with naproxen

  2018cites this paper
• Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug–Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method

  2018cites this paper
• Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics.

  2018cites this paper
• Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

  2018cites this paper
• Assessing Drug Interaction Potential of Herbal Medicine Liv.52, Smokeless Tobacco Snuff and Edible Camphor using Human Liver Microsomes

  2018cites this paper
• Cytochrome P450 2C9‐natural antiarthritic interactions: Evaluation of inhibition magnitude and prediction from in vitro data

  2018cites this paper
• Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches

  2018influential citation
• Effect of the Plasticizer DEHP in Blood Collection Bags on Human Plasma Fraction Unbound Determination for Alpha-1-Acid Glycoprotein (AAG) Binding Drugs

  2018cites this paper
• Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1

  2018influential citation
• Exploring the Role of CYP3A4 Mediated Drug Metabolism in the Pharmacological Modulation of Nitric Oxide Production

  2017cites this paper
• Evaluation of hepatic activity of immunomodulatory compounds and GSK3 inhibitors

  2017cites this paper
• Retrospective use of PBPK modelling to understand a clinical drug–drug interaction between dextromethorphan and GSK1034702

  2017cites this paper
• Non-Dissociative Sequential Metabolism of Enoxacin to a Metabolic Intermediate Complex with Cytochrome P450 1A2

  2017influential citation
• Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies

  2017cites this paper
• Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.

  2017cites this paper
• Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions

  2017cites this paper
• Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies

  2017cites this paper
• Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver

  2017cites this paper
• Potential Role of Patients’ CYP3A-Status in Clozapine Pharmacokinetics

  2017cites this paper
• Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) – a comparison with the chemical inhibition method

  2017cites this paper
• Functional Annotation of Chemical Libraries across Diverse Biological Processes

  2017cites this paper
• In vitro and in silico Approaches to Study Cytochrome P450-Mediated Interactions.

  2017cites this paper
• A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions

  2017cites this paper
• Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor

  2017cites this paper